Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Evaluable Patients
View:
Post by Infinity on Apr 14, 2024 3:32pm

Evaluable Patients

I was just looking some previous MD & A on the progress of evaluable patients.  That seems to me a major concern. on the 30th March, 2023 MD & A we had 53 evaluable patients.
Check this link for their MD & A just over a year ago

https://theralase.com/wp-content/uploads/2023/08/MDA-Q123.pdf

After a full year, we have an evaluable patients at 63.   At the same rate we are going to need 4 more years to reach 100 evaluable patients.  RDW is talking about completing the clinical study by 2024 and possible commercialization by end 2026.  I am hoping taking on Dr. Jewet as a consultant would allow TLT to step on the Gas a bit.  I am hoping the during  the next month AUA meeting and Advisory board meeting with all TLT  principal investigators in the USA would get us some Tail wind and get it going in the right direction.

Just some wishfull thinking on a Lazy Sunday Afternoon.
Comment by Alamir1111 on Apr 14, 2024 5:07pm
High  efficiency  easy 1..2 treatment no major side effects supposed to be the  cheapest treatment 10 cancer centres.smartest scientists .is there something else we are not aware of?
Comment by Legit62 on Apr 14, 2024 7:03pm
I think this all boils down to funds,no money, hard to market these sites, hard to market our treatment, a .12 cent stock price on a canadian exchange, we need to push and shove to get this done, it just takes 1 big pharma to realize the money to be made off this technology and we will all be rich, hope im not dreaming after waiting all this time
Comment by Dumbeldorfwhite on Apr 14, 2024 7:15pm
Been saying this for 2+ years yet the good ole boys club didn't want to listen. I was the one who called more pps due to the slow enrollment yet everyone kept saying the "trial is paid for" ROFL ... these guys
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250